Italy · Research startup
Italy · Resalis Therapeutics
Resalis Therapeutics is a biopharmaceutical company based in Turin, Italy, founded in 2021.
Funding reportedLast round: Series A
Follow Resalis Therapeutics and see its new rounds in your feed.Start following
About Resalis Therapeutics
Resalis Therapeutics is a biopharmaceutical company based in Turin, Italy, founded in 2021.
The company specializes in developing non-coding RNA (ncRNA) therapeutics, particularly antisense oligonucleotides that target microRNAs. Resalis combines expertise in lipid metabolism and RNA modalities to create innovative solutions for complex metabolic disorders. The company is advancing its lead candidate, RES-010, which targets microRNA-22 to address obesity, metabolic-associated fatty liver disease, and liver inflammation. RES-010 is currently in a Phase II clinical trial, demonstrating promising results in preclinical studies. Resalis also offers services in drug discovery and life sciences, focusing on ncRNA drug modality development, antisense oligonucleotide design, and lipid metabolism research. With a commitment to addressing unmet medical needs, Resalis Therapeutics aims to provide effective, disease-modifying treatments for patients suffering from metabolic dysfunction and related conditions.
What company datasets say Resalis Therapeutics raised
Funding, as reported
Founders and team
From Resalis Therapeutics's own website: 2 founders, 13 on the team.
- Alessandro TonioloChief Executive Officer
- Almut NitscheChief Development Officer
- Diana M. RøpckeChief Medical Officer
- Thomas EichingerChief Technical Development Officer
- Anna AltieriTranslational Research Lead
- Arianna CuomoPreclinical Research Associate
- Claus AnderssonNon-Executive Director
- Giulia GrilloPreclinical Research Associate
- Halina NovakNon-Executive Director
- Pietro PuglisiChairman
- Sandor BatkaiMedical Director
- Valentina AgnolonDevelopment Lead
- Valentina GaudioBusiness Analyst
On a portfolio page
Investors who name them
Each firm lists Resalis Therapeutics on its own website. That is the firm's claim, a weaker thing than a round we watched, but a named source.
The company, in detail
What they build
Known for
health carebiotechnology researchlipid metabolismrna mechanism of actionmetabolic diseasesdisease modificationmedical researchmetabolic healthhospital & health carerna-based therapiesantisense oligonucleotidemedicalobesity therapymicrorna mir-22phase 1 clinical trialtherapeutic development
Built with from their website
WordPress.orgViewport MetaCookieYesFacebook SDKPriority HintsGoogle Font APIMicrosoft ExchangeMySQLPrimeNGMicrosoft 365 Apps & Services
+8 more
Mobile FriendlyjQueryAruba DNSRSSFacebook Social PluginsArubaHTTP/3Vimeo
- Sector
- Research
- Industry code
- NAICS 541714, SIC 2834, 8731
- Region
- Piedmont
- Revenue
- 1.5M a year, as listed
- Full record
- Every detail in the company directory
Research in Italy
Startups like it
Is this your company?
Add your raise, your deck and your story, and put Resalis Therapeutics in front of investors. Or tell us what we have wrong.